Steroid-Refractory Chronic GVHD: Unmet Needs and Future Directions
Closing out his discussion, Yi-Bin Chen, MD, talks about unmet needs, ongoing clinical trials, emerging treatment options for patients with steroid-refractory chronic GVHD.
Reflections on the Case and Risk Management for Chronic GVHD
Yi-Bin Chen, MD, reflects on the patient case and outlines strategies for educating and managing patients at risk of developing chronic GVHD.
Ruxolitinib Safety in Steroid-Refractory Chronic GVHD
A brief overview of safety and adverse events in the REACH3 trial of ruxolitinib in patients with steroid-refractory chronic GVHD.
Ruxolitinib Efficacy in Steroid-Refractory Chronic GVHD
A discussion of data from the REACH3 trial and real-world data on the efficacy of ruxolitinib in patients with steroid-refractory chronic GVHD.
Treatment Options for Steroid-Refractory Chronic GVHD
Yi-Bin Chen, MD, discusses available treatment options for patients with steroid-refractory chronic GVHD.
Early Diagnosis of Chronic GVHD and Tools for Severity Assessment
Insight on early diagnosis of chronic GVHD and the tools clinicians use to assess GVHD severity.
Symptoms and Manifestations of Chronic GVHD
A comprehensive overview of the symptoms of and organs involved in chronic GVHD.
Risk Factors for Chronic GVHD and Steroid-Refractory Disease
A focused discussion on various risk factors for developing chronic GVHD and steroid-refractory disease.
Overview: A 42-Year-Old Woman With Moderate Steroid-Refractory Chronic GVHD
Yi-Bin Chen, MD, discusses the work-up, diagnosis, and treatment of a 42-year-old woman with moderate steroid-refractory chronic graft-versus-host disease (GVHD).
Unmet Needs in the Management of aGvHD
Yi-Bin Chen, MD, comments on the need for improvements in patient assessment tools, measurements of response, and therapeutic agents for the management of acute GvHD in the future.
Treatment Options for Steroid Refractory aGvHD
Yi-Bin Chen, MD, considers potential treatment options for steroid-refractory aGvHD and examines the results of the phase 3 REACH2 study of ruxolitinib.
Defining Steroid Refractory aGvHD
Yi-Bin Chen, MD, discusses diagnostic criteria and measurements of response as they relate to the case of a 50-year-old woman with steroid-refractory acute GvHD.
Clinical Risk Factors and Prophylaxis for aGvHD
Yi-Bin Chen, MD, defines acute graft-versus-host disease (aGvHD) as a complication of allogeneic transplant, discusses the clinical risk factors, and reviews prophylactic treatment options.
Predictive Prognosis and Risk-Stratification in aGvHD
Yi-Bin Chen, MD, gives insight into the current accuracy of predictive prognostics and the potential use of biomarkers to risk stratify patients with acute GvHD in the future.
Case Overview: Steroid Refractory aGvHD
Yi-Bin Chen, MD, provides an overview of the case of a 50-year-old woman with steroid-refractory acute GvHD, including initial presentation, clinical work-up, and treatment.
A 50-Year-Old Woman With Steroid-Refractory Acute Graft Versus Host Disease
Yi-Bin Chen, MD, reviews the case of a 50-year-old woman with steroid-refractory acute graft versus host disease (aGvHD) following allogeneic transplant and provides a discussion on treatment considerations for patients with aGvHD.
2 Commerce Drive Cranbury, NJ 08512